Abstract #4325

Research Polarizer Quality Control Metrics and Resulting SNR in Human Prostate Cancer Patients

Natalie Korn^1,2, Jeremy Gordon¹, Justin Delos Santos¹, Hsin-Yu Chen^1,2, Peder EZ Larson^1,2, Daniele Mammoli¹, Robert A Bok¹, Mark VanCriekinge¹, Jim Slater¹, Rahul Aggarwal³, Matthew Cooperberg³, Lynn Delos Santos¹, Jeffry Simko⁴, Susan M Noworolski^1,2, Daniel Vigneron^1,2, and John Kurhanewicz^1,2

¹Radiology and Biomedical Imaging, University of California at San Francisco, San Francisco, CA, United States, ²The Graduate Group in Bioengineering, University of California at Berkeley and San Francisco, San Francisco, CA, United States, ³Department of Urology, University of California at San Francisco, San Francisco, CA, United States, ⁴Department of Pathology, University of California at San Francisco, San Francisco, CA, United States

The number of sites performing hyperpolarized [1-¹³C]pyruvate human studies is increasing every year. We relate metrics used in quality control (QC) of a polarized sample to traditional metrics of signal quality in vivo in 24 hyperpolarized human prostate exams. The QC metrics of injected volume and injection time are significantly correlated with the maximum [1-¹³C]pyruvate SNR in vivo (r=0.68, p<0.01; r=-0.48,p=0.05, respectively) and the number of voxels with estimated usable SNR (r=0.70, p<0.01; r=-0.59, p=0.01, respectively). These metrics have improved over the course of this trial with team coordination and can be improved at other sites beginning hyperpolarized human research.

This abstract and the presentation materials are available to members only; a login is required.

Join Here